Mansfield Bio-Incubator

Akttyva team is proud to announce the National Science Foundation (NSF) Phase II #Award. This prestigious Award will be used to advance the Company’s drug-discovery engine into a software package ready to be applied at scale to develop new medicines for unmet clinical needs as well as to select and advance our lead compound to IND-enabling studies. Akttyva team Bruno Villoutreix Usamah Kayyali Mario DiPaola Kellia G. Karambizi Robert Bechard Yosef (Yossi) Landesman Lana Gladstein would like to thank our patient investors, advisors and collaborators without whom we would not have been able to get there. Brian Kirk, Ph.D. Pabel Delgado Mark Tepper, Ph.D. David Cannistraro Marcello Allegretti Marina Borisova, MBA Amanda Drobnis Alexander Margulis, Ph.D. Mansfield Bio-Incubator SVB Goodwin We also would like to thank Biomedical Advanced Research and Development Authority (BARDA) for funding an in vivo efficacy study using our lead compound. We are looking forward to developing this innovative molecule for multiple unmet needs including military applications, where it has a potential to save lives. We’d like to add that the Company is now eligible for $500,000 match from NSF for a $1,000,000 raise - so this is an invitation to the potential investors to extend their investment by this matching opportunity. Scott L. Rakestraw Muzammil Mansuri Stephen Haralampu Radha Iyengar David Donabedian Debra Peattie

#BreakingNews – 3Daughters is thrilled to announce that we have successfully closed an oversubscribed Seed financing round at $4.7 million! This round saw participation from our existing investors including Thairm Bio, Argosy Foundation, Wexford Science & Technology, LLC, University of Massachusetts Amherst, as well as new undisclosed investors. Previously, we announced the first tranche of this financing round, exceeding $2M. With 275 million women using IUDs worldwide and with women using birth control for an average of 30 years, there is a critical need for improved options and innovation in the $8 billion U.S. contraceptive market. Thanks to the funding from our investors, we’re able to work on addressing these issues with our frameless, nonhormonal, magnetic IUD (3D-001), along with our patented inserter and retriever system, that aims to eliminate the major pain points that prevent women choosing one of the most effective forms of birth control. We are endlessly grateful to our investors for their steadfast support in our mission for innovation. 3Daughters has launched a Series A financing round of $15M to fund 3D-001’s first-in-human Phase 1 study expected to start following IND approval in 2025. Read more: https://lnkd.in/ee8MxwGR #womenshealth #pressrelease #IUD #contraception

Pending AI are humbled to be announced as a semi-finalist for the nationwide Australian Technologies Competition. Our Founder and CEO, Mark P. Waller, had an opportunity to participate in an in-depth symposium over two days alongside other innovative companies shortlisted. Working alongside the fantastic B. Sara Howard, Ph.D., we are looking forward to competing in future rounds!

Is #ai just a hype or a useful tool for your #business. Come to Mansfield Bio-Incubator on June 12 at 10 am or join online to find out. #biotech #entrepreneur #startup #massachusetts https://lnkd.in/gAQUeFjw